Cerebral edema in DKA

Background

  • Most feared complication of pediatric DKA; accounts for 50-65% of all DKA deaths[1]
  • Occurs in 0.5-1% of pediatric DKA episodes (up to 4-5% with subclinical edema on imaging)[2][3]
  • Mortality rate: 21-24%; significant neurologic morbidity (10-26%) in survivors[1][4]
  • Almost all affected patients are <20 years old[3]
  • Mental status abnormalities (GCS <14) occur in 4-15% of children treated for DKA and are often associated with mild cerebral edema on imaging[1]

Pathophysiology

  • Previously attributed to osmotic shifts with rapid IV fluid administration; this model has been largely disproven
  • Current understanding favors cerebral hypoperfusion and reperfusion injury during DKA treatment as the primary mechanism[5][1]
  • Cerebral edema has been found on imaging even before treatment is initiated, including in children found dead at home from undiagnosed DKA[1]
  • Bicarbonate administration is independently associated with cerebral edema (persists after correcting for DKA severity) — avoid bicarbonate in pediatric DKA[6]

Risk Factors

  • Age <5 years
  • New-onset diabetes (first DKA presentation)
  • Severe acidosis (pH <7.1, pCO₂ <20)
  • Higher BUN at presentation (marker of dehydration severity)[6]
  • Failure of corrected sodium to rise with treatment[6]
  • Severe hyperosmolality
  • Bicarbonate administration[6]
  • Late presentation for medical evaluation
  • Previous episodes of DKA
  • Overaggressive fluid resuscitation is NOT a proven risk factor — the PECARN FLUID trial (1,389 episodes) showed neither fluid rate nor sodium content significantly affected neurologic outcomes[5]


Clinical Features

  • Typically begins 4-12 hours after onset of therapy, but may occur before treatment or up to 48 hours later[1]
    • Many children appear to be improving from DKA before deteriorating from cerebral edema
    • Can occur at presentation in new-onset diabetes (including type 2)[1]

Warning Signs (use Muir Criteria for early detection)

Diagnostic criteria (any ONE is diagnostic):[4]

  • Abnormal motor or verbal response to pain
  • Decorticate or decerebrate posture
  • Cranial nerve palsy (especially III, IV, VI)
  • Abnormal neurogenic respiratory pattern (grunting, tachypnea, Cheyne-Stokes, apneusis)

Major criteria:[4]

  • Altered mentation / fluctuating level of consciousness
  • Sustained heart rate deceleration (>20 bpm decrease) not attributable to improved intravascular volume or sleep
  • Age-inappropriate incontinence

Minor criteria:[4]

  • Vomiting
  • Headache
  • Lethargy or difficulty arousing
  • Diastolic BP >90 mmHg
  • Age <5 years

Interpretation: 1 diagnostic criterion, OR 2 major criteria, OR 1 major + 2 minor criteria → 92% sensitivity and 96% specificity for cerebral edema[4]

  • GCS alone is not sensitive enough — use the Muir criteria above[4]
  • Perform a thorough baseline neurologic exam (including cranial nerves) at presentation and document it so colleagues can identify changes


Differential Diagnosis

Hyperglycemia

Diabetic Emergencies

Diabetes Mellitus (New or Known)

Medication/Drug-Induced

Physiologic Stress Response

  • Sepsis / critical illness (stress hyperglycemia — very common in the ED)
  • Trauma / major surgery / burns
  • Acute coronary syndrome / myocardial infarction
  • Stroke (especially hemorrhagic)
  • Pancreatitis (both a cause and consequence)
  • Shock (any etiology)
  • Pain (catecholamine surge)
  • Seizure (postictal)
  • Physiologic stress alone rarely causes glucose >200 mg/dL in non-diabetics; glucose >200 in a "stress response" should prompt evaluation for undiagnosed diabetes or prediabetes

Endocrine

Pancreatic

  • Pancreatitis (acute or chronic — destruction of islet cells)
  • Pancreatic malignancy (adenocarcinoma, neuroendocrine tumors)
  • Post-pancreatectomy
  • Cystic fibrosis-related diabetes
  • Hemochromatosis (iron deposition in pancreas — "bronze diabetes")

Toxic/Overdose

Other

  • Renal failure (chronic kidney disease, acute kidney injury — impaired insulin clearance AND insulin resistance)
  • Cirrhosis / hepatic failure (impaired glycogenolysis regulation)
  • Pregnancy (gestational diabetes, steroid administration for fetal lung maturity)
  • Parenteral nutrition (TPN, dextrose-containing fluids)
  • Post-transplant diabetes (immunosuppressants)

Complications of Diabetes (Not Causes of Hyperglycemia)

These are associated conditions that may be present alongside hyperglycemia but do not themselves cause elevated glucose:

  • Also consider: hypoglycemia (most important to rule out first), cerebral venous thrombosis, intracranial hemorrhage, stroke[1]


Evaluation

  • Cerebral edema in DKA is a CLINICAL diagnosis — do NOT delay treatment for imaging[1][4]
  • Capillary glucose measurement immediately to rule out hypoglycemia as the cause of altered mental status
  • Head CT (non-contrast) — obtain after treatment has been initiated, NOT before[1]
    • CT may be normal early (sensitivity is limited); used primarily to rule out other pathology (hemorrhage, thrombosis)
    • CT may show diffuse cerebral edema, small ventricles, or loss of sulcal markings
  • Monitor corrected sodium during DKA treatment — failure of corrected sodium to rise as glucose falls suggests excess free water and increased risk[6][1]
    • Corrected Na = Measured Na + [1.6 × (glucose – 100) / 100]

Monitoring During DKA Treatment (Prevention)

  • Hourly neurologic assessments for the first 12 hours of DKA therapy (minimum), including cranial nerves[1]
    • Increase frequency to q30min in children <5 years or with pH <7.1
  • Avoid bicarbonate administration[6]
  • Follow corrected sodium — should trend upward during treatment[1]


Management[1][2]

Treat IMMEDIATELY when suspected — do not wait for imaging

Immediate Actions

  • Elevate head of bed to 30 degrees
  • Reduce IVF rate by one-third
  • Avoid intubation unless absolutely necessary (loss of hyperventilatory drive worsens cerebral edema)[1]
    • If intubation is required, maintain pCO₂ near pre-intubation level — avoid aggressive hyperventilation (associated with worse outcomes)[7]

Hyperosmolar Therapy

  • Give whichever agent is immediately available — do NOT delay treatment[8]
  • Mannitol 0.5-1 g/kg IV over 20 minutes[1]
    • May repeat in 30 min to 2 hours if inadequate response
    • Historically the most commonly used agent; best studied in this specific population
    • Disadvantage: causes osmotic diuresis (may worsen dehydration)
  • 3% Hypertonic saline 3-5 mL/kg (or 250 mL) IV over 15-30 minutes[1][8]
    • Increasingly used in pediatric ICU settings
    • One retrospective study (DeCourcey 2013) found hypertonic saline as sole agent was associated with higher mortality than mannitol alone (OR 2.71), though this had significant limitations[9]
  • If initial therapy is ineffective, give the other agent (i.e., if mannitol given first, try 3% saline; and vice versa)[1]

Additional Measures

  • Consult neurosurgery and PICU/ICU immediately
  • Treat noncardiogenic pulmonary edema if present
  • Hold insulin infusion during acute treatment of cerebral edema (the priority shifts to managing intracranial pressure)
  • Consider ICP monitoring in consultation with neurosurgery


Disposition

  • Admit PICU/ICU — all patients
  • Mortality remains high (21-24%) even with treatment; early recognition and treatment provides the best chance for good outcomes[1]


Pearls

  • Cerebral edema is a CLINICAL diagnosis — treat first, image after
  • Use the Muir criteria (not just GCS) for early detection — 92% Sn, 96% Sp
  • Perform and document a thorough neuro exam at the start of DKA treatment so changes can be identified
  • The old dogma that "rapid IVF causes cerebral edema" has been disproven by the PECARN FLUID trial[5]
  • Never give bicarbonate in pediatric DKA — it is an independent risk factor for cerebral edema[6]
  • Give whichever osmolar agent (mannitol or 3% saline) is immediately available — do not delay searching for one over the other
  • If you must intubate, match the pre-intubation pCO₂ — iatrogenic normalization of CO₂ worsens cerebral edema
  • A child improving from DKA who suddenly deteriorates = cerebral edema until proven otherwise


See Also

  • Diabetes mellitus (main)
  • DKA
  • DKA (Peds)
  • Cerebral edema
  • Herniation syndromes


References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 Glaser N, Fritsch M, Priyambada L, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022;23(7):835-856. doi:10.1111/pedi.13406
  2. ↑ 2.0 2.1 Cooke & Plotnick. Management of diabetic ketoacidosis in children and adolescents. Pediatr Rev. 2008 Dec;29(12):431-5
  3. ↑ 3.0 3.1 Glaser NS, Wootton-Gorges SL, Buonocore MH, Marcin JP, Rewers A, Strain J, et al. Frequency of subclinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes. Apr 2006;7(2):75-80.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care. 2004 Jul;27(7):1541-6.
  5. ↑ 5.0 5.1 5.2 Kuppermann N, Ghetti S, Schunk JE, et al. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med. 2018;378(24):2275-2287. doi:10.1056/NEJMoa1716816
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344(4):264-269.
  7. ↑ Marcin JP, Glaser N, Barnett P, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. 2002;141(6):793-797.
  8. ↑ 8.0 8.1 BSPED Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis. 2021.
  9. ↑ DeCourcey DD, Steil GM, Wypij D, Agus MS. Increasing use of hypertonic saline over mannitol in the treatment of symptomatic cerebral edema in pediatric diabetic ketoacidosis: an 11-year retrospective analysis of mortality. Pediatr Crit Care Med. 2013;14(7):694-700.
This page is issued from WikEM. The text is available under an unknown license unless otherwise noted. Additional terms may apply for the media files.